Introduction
Endoscopic variceal sclerotherapy (EVS) is widely accepted as an alternative to surgery for treating esophageal varices (1).
Esophageal complications of sclerotherapy have included necrotizing inflammation, ulceration, perforation, and stricture. In addition, a variety of extravariceal manifestations have been associated with EVS. While most of these are pleuropulmonary in nature (2-4), the effects on the cardiovascular system have not been fully evaluated. Someprevious reports have shown that the changes in systemic hemodynamics following EVS are minor, transient, and clinically insignificant (4-7). However,these reports concentrated on the hemodynamic changes immediately after injection, comparing measurements before and a few minutes after a single EVSsession (5-7). Sclerotherapy cannot obliterate esophagocardial varices in a single EVS session. Repeat sessions are required to obtain complete eradication ( 1 , 2). Repeated injections may expose the patient to a cumulative risk, and obliteration ofesophagocardial collateral vessels per se, may influence cardiovascular homeostasis. However, there are few reports focusing on the hemodynamic effects of chronic EVS. A single report by Bourbon et al (8) found no significant change in systemic or splanchnic hemodynamics following chronic EVS. However, in their study, only 8 patients were analyzed and the radicability ofgastroesophagealjunctional collateral vessels was uncertain. The objective of this study was to determine whether sclerotherapy affects the hepatic or systemic hemodynamicsby measuring these parameters at the inception of EVSand after obliteration of esophageal varices by EVS.
Patients and sclerotherapy procedure The study subjects consisted of 35 patients whoconsecutively received EVS between October 1991 and December 1993 in our institution. All had histologically proven cirrhosis of the liver. Twenty-two patients were Child-Pugh's class A, 1 3 were Child's class B. Theendoscopic appearance ofesophageal varices was categorized according to the classification of the Japanese Research Society for Portal Hypertension (9). In all cases, endoscopic examination revealed high-risk esophageal varices, such as enlarged, tortuous, blue varices with a positive red color sign. None of the patients had a sepsis, heart disease, or hepatorenal syndrome. The presence of extravariceal portosystemic collateral vessels was diagnosed by ultrasonography and computed tomography before the initiation of EVS. Three patients had a large splenorenal shunt and 5 had a recanalized paraumbilical vein.
Sclerotherapy was carried out in elective or prophylactic condition using a flexible endoscope (GIF Q-10, K10 Olympus Corp., Tokyo, Japan) with the patient was sedated by diazepam and pentazocine. Weemployed the method of intravariceal injection and used ethanolamine oleate as the sclerosant in all cases (1). This procedure was repeated at 7 to 10 day intervals until all varices had disappeared or had shrunk to small white varices without the red-color sign. The mean EVSsession was 2.9+0.7 times and the mean days were 18.7±7.1 in the first course of EVS.
Study protocol
The investigations described were performed before and after the first course ofEVS(5 to 10 days after the final session). During the study, patients were placed on a constant sodium diet (7 g/day). No vasoactive drugs, such as beta-blockers or nitrate were administered. The patients receiving diuretics (furosemide and/or spironolactone) continued to receive these medications at the same dose. Written informed consent was obtained prior to study from each patient. The study protocol was approved by the Hospital Ethics Committee.
Hemodynamic measurement
Under local anesthesia, a vessel dilator with a polypropylene sheath was introduced into the lumen of the right femoral vein.
A 7-F balloon-wedge pressure catheter (Goodtec, Inc., Huntington Beach, CA) was introduced into a right main hepatic vein and the wedge hepatic venous pressure and free positioned pressure were measured. A Swan-Ganz catheter (Baxter Healthcare Inc., Irvine, CA) was inserted into the pulmonary arterial trunk under fluoroscopic monitoring. The right atrial, pulmonary arterial, and pulmonary wedge pressure were measured. Pressures were measuredand recorded with a multichannel recorder (Polygraph EP 1 102, NECSan-Ai Inc., Tokyo, Japan). Cardiac output was measured by the thermodilution method. The hemodynamicmeasurements were performed in triplicate and the calculations were performed according to the formulas below: Mean arterial pressure (mmHg) = (systolic + 2-diastolic)/3 Hepatic venous pressure gradient (HVPG)(mmHg)= wedge hepatic venous pressure -free hepatic venous pressure Cardiac index (CI), systemic vascular resistance (SVR), and pulmonary vascular resistance were calculated with the standard formulas. The blood flow of the portal vein trunk was measured using a pulsed Doppler flow meter (SSA 270A, Toshiba Corp., Tokyo, Japan) (10). Flow velocity and "mean velocity offlow" (Vmean) were directly calculated by the apparatus. The flow volume (F) was calculated by the formula: F = Vmean«7cr2-6O (mL/min) where r represents the half-diameter of the vessel. Patients were studied by one of the authors (K.O.), who obtained three consecutive measurements of flow velocity and vessel diameter from each patient. The mean coefficient of variation of portal flow as 9.4±3.0%.
Measurement of circulating plasma volume The circulating plasma volume was measured by the dye dilution method (ll). Briefly, 5, 8, ll, and 14 minutes after intravenous injection of 0.5 mg/kg of indocyanine green, a blood sample was drawn from the peripheral vein. The absorbance of the serum sample at 805 nmwas plotted against time on a semilogarithmic graph. The circulating plasma volumewas calculated from the estimated indocyanine green concentration at zero min. The total blood volume was calculated from the circulating plasma volume and the hematocrit.
Analytical determinations At 9 AMof the same day as the hemodynamic study, blood samples were drawn for determination of standard liver function tests , total bile acid, plasma renin activity , plasma aldosterone concentration, and angiotensin II levels. A sample from a 24-hour urine collection wastaken for determination of 6-keto prostaglandin Flot. Serum total bile acid (normal value <1 1 |Limol/L) was determined using the method of direct photometry. Plasma renin activity (normal value = 0.1 to 0.56 ng-LT^sec"1), aldosterone concentration (normal value = 55 to 333 pmol/L), angiotensin II level (normal value <60 pg/ml), and urinary excretion of 6-keto prostaglandin Floc were measured using commercial radioimmunoassay kits. The urinary creatinine concentration wasmeasuredto allow normalization of the excretion of urinary metabolite.
Statistics
The results are presented as mean±SD. Paired two-tailed student's t-tests were used for meancomparisons between two groups. Spearmenn' s rank correlation and linear coefficients of correlation were also used in the analysis of the results. Multiple logistic regression was employed for multivariating model.
SASwas used for statistical analyses ( 12). Results were considered statistically significant at p<0.05.
Results

Clinical characteristics of the patients
The clinical data of the patients are summarized in Table 1 
Discussion
Variceal hemorrhage is often a dramatic event resulting in marked and prolonged alterations in the systemic and splanchnic hemodynamics, and frequently results in deleterious effects on hepatic function (13). To analyze the hemodynamic effects of chronic EVS under stable condition, we did not enroll patients who were undergoing emergent EVS. In order to avoid systemic hemodynamic alterations by the direct effects of the injected sclerosant, sedation, and endoscopy procedure (5, 7), we performed the second hemodynamic measurement 5 to 10 days after the final EVS session.
In the present study, there was a significant alteration in systemic hemodynamics following EVS in group II patients. Additionally, the serum bile acid level, which positively correlates with the portal systemic shunt ratio ( 14), was significantly decreased in these patients. Whereas systemic hemodynamics and serum bile acid levels remained unchanged in group I patients. As the variceal size and the total dose of sclerosant was markedly low in group I patients, minor eradication of collateral vessels seems to lead to the lack of hemodynamic change in patients with group I. From our findings, it appears that obliteration of esophageal varices by EVS significantly reverses the hyperdynamic circulatory state toward normal in patients with cirrhosis. In contrast, Bourbon et al (8) found no significant change in systemic hemodynamics after chronic EVS using polidocanol as a sclerosant. They also stated that the azygos vein blood flow, which reflects the gastroesophageal collateral blood flow (15), did not change after EVS. In the present study, the azygos vein blood flow significantly decreased from 50512 1 0 to 233199 ml/min (p<0.02) in 5 patients in whom we could measure the blood flow. Since ethanolamine oleate is superior to polidocanol for devascularizing collateral vessels (16), the obliteration of collateral vessels seems to be incomplete in patients of Bourbon et al (8) . To our knowledge, this is the first study showing a significant alteration in systemic hemodynamics in patients receiving chronic EVS.
Hemodynamic changes immediately following variceal injection include prompt increases in PAP and pulmonary vascular resistance which return to baseline values within 60 to 120 minutes (5-7). These hemodynamic changes are attributable to pulmonary capillary injury by sclerosant entry into the pulmonary circulation via gastroesophageal collateral vessels (3-7). In the present study, the characteristic hemodynamic changes after the first course of EVS were significant decreases in PAP, PCWP, RAP, CI, and an increase in SVR, without changes in pulmonary vascular resistance. These findings contrast distinctly with the transient hemodynamic changes seen immediately after injection (5-7). Therefore, it is unlikely that the hemodynamic changes after chronic EVS depend on the cumulative effects of pulmonary capillary injury by repeated injections. Since the percentage change in CI was positively correlated with that in PAP and PCWP, and negatively correlated with that in SVR, the primary hemodynamic effect seems to be a decrease in CI. The decrease in PAP, PCWP, and the increase i n SVR all appear to be secondary to the fall in CI.
The Anintriguing possibility is the direct role ofgastroesophageal junctional collateral vessel obliteration by EVS. We found a significant decrease in the serum bile acid concentrations and azygos vein blood flow after chronic EVS. These findings denote the decrease in portal systemic shunt flow. Since portal systemic shunting acts in an analogous hemodynamic fashion to a peripheral arteriovenous fistula (20), venous blood flow returning to the systemic circulation appears to decrease commensurate with obliteration ofesophageal varices. As the major factor determining cardiac output is the rate of venous return undernormal circumstances (2 1), this strongly suggests thatthe decrease in cardiac preload plays a major role in the decrease in CI. Indeed, transjugular intrahepatic portosystemic shunting is shown to worsen the hyperdynamic circulatory state via an increase in cardiac preload in patients with cirrhosis mainly on three factors; splanchnic arterial inflow, resistance to portal flow in the liver, and resistance in collateral vessels. The present results suggest that the fall in HVPG following EVS is related to the decrease in portal inflow resulting from the reduced CI. The role of portal inflow, which maintains and aggravates the portal-hypertensive state is also supported by the fact that propranolol decreases the portal pressure via a decrease in CI ( 1 7). In patients with large extravariceal collaterals, the decline in HVPG may be attributable to the decompression by these large shunts. Korula and Rails (27) 
